



Atty. Dkt. No. 032931-0253

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrew D. MURDIN et al.
Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF
Appl. No.: 09/868,987
Filing Date: October 1, 2001
Examiner: Padmavathi Baskar
Art Unit: 1645
Confirmation Number: 7970

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

08/24/2006 SDENB0B1 00000093 09868987

01 FC:1006

100.00 0P



Atty. Dkt. No. 032931-0253

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

The relevance of the references listed on the PTO/SB/08 is described in the Amendment being filed herewith. Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date: August 23, 2006

By Michele M. Simkin

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5538
Facsimile: (202) 672-5399

Michele M. Simkin
Attorney for Applicant
Registration No. 34,717



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 23, 2006 <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/868,987
		Filing Date	10/1/2001
		First Named Inventor	Andrew D. Murdin
		Group Art Unit	1645
		Examiner Name	Padmavathi Baskar
		Attorney Docket Number	032931-0253
Sheet	1	of	2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A1	Howard RF, Jacobson KC, Rickel E, Thurman. Analysis of inhibitory epitopes in the Plasmodium falciparum rhoptry protein RAP-1 including identification of a second inhibitory epitope. J. Infect Immun. 1998 Jan; 66(1):380-6. [Abstract]	
	A2	AbD Serotec Excerpt from technical brochure from www.ab-direct.com.	
	A3	Ayyildiz. Technical Approach to Generate Polyclonal Antibodies Against Bacterially Expressed GST-PYK-C. Tr. J. Medical Sciences. 29 (1999) 355-360. [Abstract]	
	A4	Cassill JA, Whitney M, Joazeiro CA, Becker A, Zuker CS. Isolation of Drosophila genes encoding G protein-coupled receptor kinases. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11067-70. [Pages 11067 & 11068]	
	A5	Lutzelschwab R, Klambt C, Rossa R, Schmidt O. A protein product of the Drosophila recessive tumor gene, l (2) giant gl, potentially has cell adhesion properties. EMBO J. 1987 Jun;6(6):1791-1797. [Pages 1791 & 1792]	
	A6	Schoneck R, Plumas-Marty B, Taibi A, Billaut-Mulot O, Loyens M, Gras-Masse H, Capron A, Ouaisi A. Trypanosoma cruzi cDNA encodes a tandemly repeated domain structure characteristic of small stress proteins and glutathione S-transferases. Biol Cell. 1994;80(1):1-10. [Pages 1 & 2]	
	A7	Philippe B, Brion JP, Coppens E, Octave JN. Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein. J Neurosci Res. 1996 Dec 15;46(6):709-19. [Abstract]	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 23, 2006 <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/868,987
		Filing Date	10/1/2001
		First Named Inventor	Andrew D. Murdin
		Group Art Unit	1645
		Examiner Name	Padmavathi Baskar
Sheet 2 of 2		Attorney Docket Number	032931-0253

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A8	Yu H, Nakano Y, Yamashita Y, Oho T and Koga T. Effects of antibodies against cell surface protein antigen PAC- glucosyltransferase fusion proteins on glucan synthesis and cell adhesion of Streptococcus mutans. Infect. Immun., 06 1997, 2292-2298, Vol 65, No. 6 [Abstract]	
	A9	Zhou FC, Xu Y, Bledsoe S, Lin R, Kelley MR. Serotonin transporter antibodies: production, characterization, and localization in the brain. Brain Res Mol Brain Res. 1996 Dec 31;43(1-2):267-78. [Abstract]	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁹ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.